SGI
NBIX icon

Summit Global Investments’s Neurocrine Biosciences NBIX Stock Holding History

Summit Global Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96M Buy
29,424
+12,341
+72% +$1.83M 0.27% 45
2026
Q1 		$2.25M Sell
17,083
-7,721
-31% -$1.02M 0.13% 83
2025
Q4 		$3.52M Sell
24,804
-11,351
-31% -$1.64M 0.21% 56
2025
Q3 		$5.08M Buy
36,155
+24,639
+214% +$3.34M 0.3% 53
2025
Q2 		$1.45M Buy
11,516
+638
+6% +$73.2K 0.09% 136
2025
Q1 		$1.2M Sell
10,878
-21,182
-66% -$2.68M 0.09% 138
2024
Q4 		$4.38M Sell
32,060
-21,517
-40% -$2.66M 0.27% 81
2024
Q3 		$6.17M Sell
53,577
-24,024
-31% -$3.29M 0.39% 54
2024
Q2 		$10.7M Buy
77,601
+28,124
+57% +$3.86M 0.72% 28
2024
Q1 		$6.82M Buy
49,477
+8,744
+21% +$1.19M 0.51% 46
2023
Q4 		$5.37M Buy
40,733
+10,696
+36% +$1.23M 0.35% 66
2023
Q3 		$3.38M Buy
30,037
+406
+1% +$42.8K 0.23% 96
2023
Q2 		$2.79M Buy
29,631
+646
+2% +$63.1K 0.19% 115
2023
Q1 		$2.93M Buy
28,985
+2,309
+9% +$240K 0.23% 105
2022
Q4 		$3.19M Buy
26,676
+14,979
+128% +$1.75M 0.27% 103
2022
Q3 		$1.24M Buy
+11,697
New +$1.19M 0.11% 174

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Summit Global Investments's NBIX Position: Q2 2026 in Review

Summit Global Investments increased its Neurocrine Biosciences (NBIX) stake by 72% in Q2 2026, buying an estimated $1.83M and bringing the position to 29,424 shares worth $4.96M. The position accounts for 0.27% of the portfolio, ranked #45.

Summit Global Investments first reported a position in NBIX in Q3 2022 and has held it in 16 quarters since. The position peaked at $10.7M in Q2 2024. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Summit Global Investments held 29,424 shares of Neurocrine Biosciences worth $4.96M as of Q2 2026.
  • Summit Global Investments bought 12,341 Neurocrine Biosciences shares in Q2 2026, an estimated $1.83M.
  • Neurocrine Biosciences made up 0.27% of Summit Global Investments's portfolio in Q2 2026, its #45 holding.
  • Summit Global Investments first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 16 quarters since.
  • Summit Global Investments's Neurocrine Biosciences position peaked at $10.7M in Q2 2024.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.